Insamo

Insamo combines machine-learning molecular design, ultra-high-throughput biology and parallel synthetic chemistry in an automated design-synthesize-test cycle. Its own site says the process draws on trillions of proprietary experimental data points to explore drug-like chemical space.

The company's launch release says the platform can synthesize and screen libraries containing trillions of molecules and find high-affinity ligands with limited prior target information. These are discovery capabilities; the examined sources do not establish clinical efficacy or a shorter development timeline.

Insamo's public materials describe a discovery platform and preclinical candidate generation rather than a marketed medicine. The examined first-party pages do not state clinical efficacy or pharmacokinetic outcomes for an Insamo therapy.

The platform is designed to optimize oral availability, membrane permeability and target binding, but those design goals require program-level validation. Its launch release says macrocyclic peptides have been challenging to translate into the clinic and does not report an approved therapy.

Insamo combines machine learning-driven molecular design, ultra high-throughput molecular biology, and parallel synthetic chemistry to generate preclinical candidates. The platform can screen trillions of molecules and identify high-affinity ligands for targets with limited structural or druggability information.

This approach enables the discovery of oral cyclic peptides that retain antibody-like binding while penetrating cell membranes, addressing intracellular targets that are often inaccessible to conventional large-molecule therapeutics.